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To the Editor: 
We previously reported in the JTO the case of a 56-year-old woman with a metastatic pulmonary 
adenocarcinoma in complete remission under Nivolumab, who developed a typical eosinophilic 
fasciitis with a concomitant immune cholangitis, both found considered as adverse events of the 
immune checkpoint inhibitor (ICI) 1. 
Nonetheless, no improvement was observed after ICI discontinuation, and a dramatic worsening 
was noticed despite a combination of corticosteroids and methotrexate therapy, as the fasciitis 
extended to the whole body-involving the face- and causing a diffuse and painful stiffness.  
Because the immune disease was still worsening, 9 months after Nivolumab withdrawal, and 
considering the absence of malignancy relapse on CT scan reassessment, methotrexate was 
switched for Sirolimus, a m-TOR inhibitor which had also shown efficacy in a case of idiopathic 
eosinophilic fasciitis2.  
A remarkable improvement was rapidly obtained, and after 6 months of therapy, the patient 
regained a close to normal range of motion of her large joints, with a clear improvement in skin 
thickening involving the fingers and the dorsum of the hands, which were previously stuck in 
flexion contracture, as illustrated in Figure 1. So far, the cancer is still in remission, despite the 
absence of antineoplastic agents. 
 
Data regarding the management of steroid refractory idiopathic eosinophilic fasciitis are scarce. 
Concerning the specific situation of ICI-immune-mediated fasciitis, no practical guidelines are 
available, and especially in the case of fasciitis that are refractory to ICI cessation and classical 
corticosteroids therapy. Although considered as a rare affection, ICI-immune mediated fasciitis 
should deserve special attention to explore new therapeutic approaches, as the treatments that have 
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proven efficient in other rheumatic toxicities, e.g. in arthritis, might not be broadened to this 
specific ICI adverse event even if their pathophysiology share some similarities 3,4.  
Hence, this observation suggests a noticeable efficacy of Sirolimus in Nivolumab related fasciitis, 
raising the question that the mTOR pathway could be a promising target in the field of ICI-
immune-mediated diseases. 
Captions  
Figure 1. Clinical evolution after 6 months of Sirolimus therapy: 
A (upper left picture), B (lower left picture): Skin thickening with contracture of the fingers 
C (upper right picture), D (lower right picture): After 6 months of Sirolimus, marked improved 
mobility of the joints 
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